Vishal Gulati

Digital Health Companies: Get The Evidence or Get Packing

January 5, 2016

All regulators, the FTC and the FDA are all getting less shy about calling out companies that are blatantly making claims that they cannot substantiate or otherwise risk harming the physical (or financial) well being of users. FTCs crackdown on dermatology apps, and the FDA’s move on 23&Me (partially relaxed) and fining Pathway Genomics are all signs of a maturing sector.

Not so good news if you are Lumosity, but good news if you have real data showing real patient benefit.